Jubilant Pharmova Limited — Updates, 29-07-2025: Press Release

Jubilant Pharmova delivered a strong Q1'FY26. Revenue rose 10% YoY to Rs. 1,901 Cr, with EBITDA increasing 14% to Rs. 302 Cr, expanding margins by 60 bps. Normalised PAT surged 48% to Rs. 103 Cr. Growth was broad-based, notably in Radiopharma and CDMO Sterile Injectables. The Spokane Line 3 is on track for commercial production in FY26, with peak utilization now expected in three years due to strong big pharma interest. The API business will transfer to Jubilant Biosys for enhanced operational efficiency. Generics profitability improved, and new product launches are planned. Net debt marginally increased due to capex.